Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

turoctocog alfa

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Factor VIII (FVIII) is indicated for the prevention or treatment of bleeding in patients with hemophilia A. FVIII product… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2016
2016
Essentials Chromogenic assays may be less variable than one‐stage clot assays for measuring modified factor VIII. Chromogenic… Expand
Review
2016
Review
2016
Background No head-to-head trials comparing recombinant factor VIII (rFVIII) products currently exist. This was a matching… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Review
2015
Review
2015
Turoctocog alfa (NovoEight®) is a human recombinant coagulation factor VIII (rFVIII) for the treatment of patients with… Expand
2015
2015
Recombinant factor VIII (rFVIII) products provide a safe and efficacious replacement therapy for prevention and treatment of… Expand
Review
2015
Review
2015
Turoctocog alfa (NovoEight®) is a new recombinant factor VIII (rFVIII) with a truncated B domain and a high degree of tyrosine… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Review
2014
Review
2014
Turoctocog alfa (NovoEight®) is a recombinant factor VIII (rFVIII) with a truncated B‐domain made from the sequence coding for 10… Expand
2014
2014
Haemophilia and its treatment interfere with patients' life, so health‐related quality of life (HRQoL) should be assessed when… Expand
Review
2014
Review
2014
Hemophilia A (HA) represents one of the most common genetic bleeding disorders worldwide and results from a deficiency in factor… Expand
Highly Cited
2013
Highly Cited
2013
Recombinant factor VIII (rFVIII) products provide a safe and efficacious replacement therapy for prophylaxis and treatment of… Expand